Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes

被引:25
|
作者
Rauch, Philipp J. [1 ,2 ,3 ]
Gopakumar, Jayakrishnan [4 ]
Silver, Alexander J. [5 ]
Nachun, Daniel [4 ]
Ahmad, Herra [4 ]
Mcconkey, Marie [1 ,2 ,3 ]
Nakao, Tetsushi [1 ,2 ,3 ,6 ,7 ,8 ]
Bosse, Marc [4 ]
Rentz, Thiago [8 ]
Gonzalez, Nora Vivanco [3 ]
Greenwald, Noah F. [4 ]
Mccaffrey, Erin F. [4 ]
Khair, Zumana [4 ]
Gopakumar, Manu [9 ]
Rodrigues, Kameron B. [4 ]
Lin, Amy E. [1 ,2 ,3 ,8 ]
Sinha, Eti [4 ]
Fefer, Maia [8 ]
Cohen, Drew N. [1 ]
Vromman, Amelie [8 ]
Shvartz, Eugenia [8 ]
Sukhova, Galina [8 ]
Bendall, Sean [4 ]
Angelo, Michael [4 ]
Libby, Peter [8 ]
Ebert, Benjamin L. [1 ,2 ,3 ,10 ]
Jaiswal, Siddhartha [4 ,11 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Broad Inst Harvard, Cambridge, MA 02215 USA
[3] MIT, Cambridge, MA USA
[4] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[5] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA
[7] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[8] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, Boston, MA USA
[9] Stanford Univ, Dept Elect Engn, Stanford, CA USA
[10] Howard Hughes Med Inst, Boston, MA 02115 USA
[11] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA
来源
NATURE CARDIOVASCULAR RESEARCH | 2023年 / 2卷 / 09期
基金
日本学术振兴会;
关键词
CELL SELF-RENEWAL; CLONAL HEMATOPOIESIS; MECHANISMS; PROTEINS; REVEALS; ROLES; MICE;
D O I
10.1038/s44161-023-00326-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the presence of a cancer-associated somatic mutation in white blood cells in the absence of overt hematological malignancy. It arises most commonly from loss-of-function mutations in the epigenetic regulators DNMT3A and TET2. CHIP predisposes to both hematological malignancies and atherosclerotic cardiovascular disease in humans. Here we demonstrate that loss of Dnmt3a in myeloid cells increased murine atherosclerosis to a similar degree as previously seen with loss of Tet2. Loss of Dnmt3a enhanced inflammation in macrophages in vitro and generated a distinct adventitial macrophage population in vivo which merges a resident macrophage profile with an inflammatory cytokine signature. These changes surprisingly phenocopy the effect of loss of Tet2. Our results identify a common pathway promoting heightened innate immune cell activation with loss of either gene, providing a biological basis for the excess atherosclerotic disease burden in carriers of these two most prevalent CHIP mutations.
引用
收藏
页码:805 / +
页数:32
相关论文
共 50 条
  • [21] Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
    Huber, Sandra
    Hutter, Stephan
    Baer, Constance Regina
    Meggendorfer, Manja
    Hoermann, Gregor
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    BLOOD, 2024, 144 : 1820 - 1820
  • [22] Aortic valve calcification is promoted by clonal hematopoiesis associated with DNMT3A and TET2 gene driver mutations
    Abplanalp, W.
    Schuhmacher, B.
    Mas-Peiro, S.
    Zuriaga, M. A.
    Matesanz, N.
    Fuster, J. J.
    John, D.
    Muhly-Reinholz, M.
    Vasa-Nicotera, M.
    Merten, M.
    Hoffmann, J.
    Dimmeler, S.
    Zeiher, A. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [23] Double somatic mosaic mutations in TET2 and DNMT3A—origin of peripheral T cell lymphoma in a case
    Tran B. Nguyen
    Mamiko Sakata-Yanagimoto
    Rie Nakamoto-Matsubara
    Terukazu Enami
    Yufu Ito
    Toshikata Kobayashi
    Naoshi Obara
    Yuichi Hasegawa
    Shigeru Chiba
    Annals of Hematology, 2015, 94 : 1221 - 1223
  • [24] IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias
    Kosmider, Olivier
    LaRochelle, Olivier
    Coude, Marie-Magdelaine
    Mansat-De Mas, Veronique
    Delabesse, Eric
    Comillet-Lefebvre, Pascale
    Bhuichet, Odile
    Recher, Christian
    Delmer, Alain
    Raynaud, Sophie
    Lacombe, Catherine
    Bernard, Olivier
    Ifrah, Norbert
    Dreyfus, Francois
    Fontenay, Michaela
    BLOOD, 2011, 118 (21) : 1517 - 1518
  • [25] Correlation of DNA methylation of DNMT3A and TET2 with oral squamous cell carcinoma
    Li, Xueming
    Li, Zaikun
    Gao, Qingxi
    Peng, Yanan
    Yu, Yang
    Hu, Tenglong
    Wang, Wei
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [26] Correlation of DNA methylation of DNMT3A and TET2 with oral squamous cell carcinoma
    Xueming Li
    Zaikun Li
    Qingxi Gao
    Yanan Peng
    Yang Yu
    Tenglong Hu
    Wei Wang
    Discover Oncology, 15
  • [27] The Impact of Dnmt3a or Tet2 CH on Alzheimer's Disease in a Murine Model
    Wathan, Trisha K.
    Florez, Marcus A.
    Fernandez-Sanchez, Josaura V.
    King, Katherine Y.
    BLOOD, 2022, 140
  • [28] TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
    Maifrede, Silvia
    Bac Viet Le
    Nieborowska-Skorska, Margaret
    Golovine, Konstantin
    Sullivan-Reed, Katherine
    Dunuwille, Wangisa M. B.
    Nacson, Joseph
    Hulse, Michael
    Caruso, Lisa Beatrice
    Gazze, Zachary
    Lian, Zhaorui
    Padella, Antonella
    Chitrala, Kumaraswamy
    Bartholdy, Boris
    Matlawska-Wasowska, Ksenia
    Di Marcantonio, Daniela
    Simonetti, Giorgia
    Greiner, Georg
    Sykes, Stephen M.
    Valent, Peter
    Paietta, Elisabeth M.
    Fernandez, Hugo F.
    Tallman, Martin S.
    Litzow, Mark
    Minden, Mark D.
    Huang, Jian
    Martinelli, Giovanni
    Vassiliou, George S.
    Tempera, Italo
    Piwocka, Katarzyna
    Johnson, Neil
    Challen, Grant
    Skorski, Tomasz
    BLOOD, 2020, 136
  • [29] DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms
    Haran, Arnon
    Wasserstrom, Avital
    Aumann, Shlomzion
    Vainstein, Vladimir
    Kazoom, Romi
    Jelinek, Batia Roth
    Arad, Ariela
    Buchman, Noa
    Shai, Ela
    Kalish, Yossi
    Gatt, Moshe E.
    Zimran, Eran
    BLOOD, 2024, 144 : 3189 - 3190
  • [30] Resistance to Inotuzumab Ozogamicin in a B-ALL Patient with TET2 and DNMT3A Mutations and Myeloid Lineage Switch
    Hergott, Christopher B.
    Kim, Annette S.
    Wadleigh, Martha
    Lindsley, R. Coleman
    BLOOD, 2018, 132